Shanghai Model Organisms Center(SH:688265)2025-04-28 15:15Financial Performance - The company plans not to distribute profits for the fiscal year 2024, with no cash dividends or stock bonuses, and will roll over the undistributed profits to the next fiscal year[7]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[5]. - The company reported a significant increase in revenue, achieving a total of $150 million for the fiscal year, representing a 25% year-over-year growth[17]. - The company's operating revenue for 2024 reached ¥381,239,513.99, representing a 4.01% increase compared to ¥366,548,781.43 in 2023[24]. - The net profit attributable to shareholders was ¥6,495,504.05, a significant turnaround from a loss of ¥20,582,607.05 in the previous year[24]. - The net cash flow from operating activities increased by 256.35% to ¥71,564,019.48, up from ¥20,082,247.66 in 2023[24]. - The basic earnings per share improved to ¥0.08 from a loss of ¥0.26 in 2023[25]. - The company achieved a revenue of 381.24 million yuan, representing a year-on-year growth of 4.01%[35]. - The net profit attributable to the parent company was approximately 6.50 million yuan, marking a turnaround from loss to profit[35]. - The company reported a decrease in financial expenses, mainly due to increased exchange gains and reduced interest expenses[134]. Risk Management - The company has detailed potential risks in its operations, which are outlined in the report[5]. - The company has a comprehensive risk awareness regarding future plans and development strategies[8]. - The company is at risk of significant profit fluctuations due to potential industry slowdowns and reduced order volumes, which could impact its profitability[113]. - The company faces risks related to the potential obsolescence of its core gene editing technologies if new, more efficient methods emerge and it fails to adapt[114]. - The company is exposed to risks from potential changes in tax incentives and government subsidies, which could affect profitability[123]. - The company faces risks related to market competition, particularly from domestic and international peers in the gene-modified animal model sector[117]. Research and Development - The company is investing $10 million in R&D for new technologies aimed at improving drug development processes[17]. - Research and development expenses accounted for 19.67% of operating revenue, a decrease of 2.22 percentage points from 21.89% in 2023[25]. - The total R&D investment for the year was ¥74,981,116.58, a decrease of 6.55% compared to the previous year[99]. - The company has developed over 21,000 models, including more than 13,000 standardized models and over 8,200 customized models[36]. - The company has developed a series of humanized animal models, including drug target humanized models and rare disease models, to meet the growing demand for precision medicine[171]. - The company is focusing on expanding its research and development capabilities, particularly in molecular biology and biochemistry, to drive innovation[199]. Market Expansion - The company is expanding its market presence in Europe, targeting a 15% market share by the end of the next fiscal year[17]. - The company is actively expanding its overseas market presence, contributing to faster growth in international business revenue[26]. - The company is exploring new strategies to optimize its supply chain and reduce operational costs[198]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 200 million allocated for potential deals[197]. - The company is focused on expanding its market presence and enhancing its product offerings through new technology development[198]. - The company is committed to enhancing its core competencies by fostering a multidisciplinary team capable of driving advanced research initiatives[104]. Corporate Governance - A standard unqualified audit report was issued by Zhonghui Certified Public Accountants for the company[6]. - The board of directors and management have confirmed the accuracy and completeness of the annual report, assuming legal responsibility for any misstatements[5]. - The company has not disclosed any special arrangements in corporate governance[10]. - The company has established a stock incentive plan for 2025, with a total of 1.3 million restricted shares, of which 1.04 million shares will be granted initially to 84 individuals[51]. - The company appointed Wang Mingjun as the acting CFO following the resignation of the previous CFO Zhou Rongxin due to personal reasons[200]. Product Development - New product launches included a cutting-edge gene editing tool, expected to enhance research capabilities and drive future sales[17]. - The company has developed various gene-modified mouse models for specific applications, including humanized models for drug testing and disease research[95]. - The company is developing a humanized antibody screening platform to support personalized medicine and drug development[172]. - The company has established a comprehensive "mouse hospital" platform to support various research needs in genetic function studies and pharmacological efficacy[100]. Customer Engagement - User data showed a 40% increase in active users, reaching 1.2 million by the end of the fiscal year[17]. - User data indicates a steady increase in customer engagement and retention rates, reflecting positive market reception[198]. - The company has a strong customer base, providing services to over 950 research clients and more than 720 industrial clients, including renowned universities and pharmaceutical companies[111]. Financial Strategy - The company is focusing on cost control by implementing comprehensive budget management and optimizing procurement processes[50]. - The company aims to broaden its financing channels and improve the efficiency of fundraising to support sustainable and high-quality development[178]. - The company is committed to establishing a comprehensive service system that aligns with the demands of precision medicine, focusing on high-growth potential clients and partners[187].